Focuses on Development Therapeutics for Neurological Disorders, Mainly on Drugs That Target Protein Aggregates, and a Non-Invasive BCI Technology
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on development therapeutics for neurological disorders, mainly on drugs that target protein aggregates. A non-invasive brain computer interface (BCI) technology has also been discussed.
Immunotherapeutics for cancer and other therapeutic indications have been highlighted with a focus on single domain and radiolabeled antibodies. Emerging therapeutic strategies such as gene writing, and biomolecular condensates have also been discussed. A few innovations covering plant-based expression of recombinant proteins, protein purification, and protein stabilization have also been captured.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
1. Innovations in Life Sciences, Health & Wellness
- Technology Boosting Natural Repair Mechanism
- Small-Molecule Drug That Improves Cognition
- Athira Pharma Inc. - Investor Dashboard
- Trehalose Protein Stabilizer
- Autophagy Activation Technology
- Seelos Therapeutics - Investor Dashboard
- Potential Disease Modifying Antibody
- Antibody Targeting Misfolded Proteins
- Bioarctic AB - Investor Dashboard
- Enabling Next Generation Microbiome Research
- E[Datascientist] Provides New Opportunities for Microbiome Research
- Eagle Genomics - Investor Dashboard
- Developing Novel Single Domain Antibody Therapeutics
- Breaking Down Large-Sized Heavy Chain Antibodies to Single-Domain Antibodies
- Inhibrx - Investor Dashboard
- Simplified Protein Purification Technology
- Clim™ Affinity Tag System to Purify Some of the Most Challenging Proteins
- Trialtus Bioscience - Investor Dashboard
- Radio-Immunotherapeutic Technology for Cancer Care
- Betalutin® Enters Phase 2B Clinical Trials
- Nordic Nanovector - Investor Dashboard
- Small Molecules for Treatment of IPF
- Infectious Disease Management by Next Generation Sequencing and AI
- Non-Invasive Brain Signal Recording Technology
- Structure-Based Design of Undruggable Targets
- Gene Writing for Treating Genetic Diseases
- Instrument-Free Molecular POC Diagnostic Tests
- Unlocking Biomolecular Condensates’ Therapeutic Potential
- Plant Expression System for Production of Therapeutics
2. Key Contacts
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Athira Pharma Inc.
- Bioarctic AB
- Eagle Genomics
- Inhibrx
- Nordic Nanovector
- Seelos Therapeutics
- Trialtus Bioscience
